97 related articles for article (PubMed ID: 1721260)
1. Monitoring FK 506 concentrations in plasma and whole blood.
Jusko WJ; D'Ambrosio R
Transplant Proc; 1991 Dec; 23(6):2732-5. PubMed ID: 1721260
[TBL] [Abstract][Full Text] [Related]
2. Validation and quality assurance program for monitoring tacrolimus (FK 506) concentrations in plasma and whole blood.
D'Ambrosio R; Girzaitis N; Jusko WJ
Ther Drug Monit; 1993 Oct; 15(5):414-26. PubMed ID: 7504339
[TBL] [Abstract][Full Text] [Related]
3. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring.
Winkler M; Wonigeit K; Undre N; Ringe B; Oldhafer K; Christians U; Pichlmayr R
Transplant Proc; 1995 Feb; 27(1):822-5. PubMed ID: 7533433
[No Abstract] [Full Text] [Related]
4. Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods.
Akbas SH; Ozdem S; Caglar S; Tuncer M; Gurkan A; Yucetin L; Senol Y; Demirbas A; Gultekin M; Ersoy FF; Akaydin M
Clin Biochem; 2005 Jun; 38(6):552-7. PubMed ID: 15885236
[TBL] [Abstract][Full Text] [Related]
5. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance.
Piekoszewski W; Chow FS; Jusko WJ
Drug Metab Dispos; 1993; 21(4):690-8. PubMed ID: 7690698
[TBL] [Abstract][Full Text] [Related]
6. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression.
Winkler M; Ringe B; Baumann J; Loss M; Wonigeit K; Pichlmayr R
Clin Chem; 1994 Dec; 40(12):2247-53. PubMed ID: 7527306
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods.
Bartlomiejczyk I; Zochowska D; Sanko-Resmer J; Matuszewicz D; Paczek L
Transplant Proc; 2006; 38(1):94-6. PubMed ID: 16504673
[TBL] [Abstract][Full Text] [Related]
8. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients.
Minematsu T; Sugiyama E; Kusama M; Hori S; Yamada Y; Ohtani H; Sawada Y; Sato H; Takayama T; Sugawara Y; Makuuchi M; Iga T
Transplant Proc; 2004 Jun; 36(5):1506-11. PubMed ID: 15251372
[TBL] [Abstract][Full Text] [Related]
9. More on the reliability of the microparticle enzyme immunoassay (MEIA) for therapeutic tacrolimus monitoring.
Hermida J; Tutor JC
Clin Lab; 2003; 49(9-10):471-4. PubMed ID: 14572203
[TBL] [Abstract][Full Text] [Related]
10. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients.
Akbas SH; Yavuz A; Tuncer M; Yurdakonar E; Akcit F; Gurkan A; Demirbas A; Gultekin M; Ersoy F; Akaydin M
Transplant Proc; 2004; 36(1):86-8. PubMed ID: 15013308
[TBL] [Abstract][Full Text] [Related]
12. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
Ventura E; Bonardet A; Pageaux GP; Mourad G; Cristol JP
Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
[TBL] [Abstract][Full Text] [Related]
14. FK 506: monitoring in plasma or in whole blood?
Beysens AJ; Wijnen RM; Beuman GH; van der Heyden J; Kootstra G; van As H
Transplant Proc; 1991 Dec; 23(6):2745-7. PubMed ID: 1721263
[No Abstract] [Full Text] [Related]
15. Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group.
Transplant Proc; 1991 Dec; 23(6):3085-8. PubMed ID: 1721367
[No Abstract] [Full Text] [Related]
16. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells.
Capron A; Musuamba F; Latinne D; Mourad M; Lerut J; Haufroid V; Wallemacq PE
Ther Drug Monit; 2009 Apr; 31(2):178-86. PubMed ID: 19057467
[TBL] [Abstract][Full Text] [Related]
17. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood.
Koster RA; Dijkers EC; Uges DR
Ther Drug Monit; 2009 Feb; 31(1):116-25. PubMed ID: 19065123
[TBL] [Abstract][Full Text] [Related]
18. A novel approach for prediction of tacrolimus blood concentration in liver transplantation patients in the intensive care unit through support vector regression.
Van Looy S; Verplancke T; Benoit D; Hoste E; Van Maele G; De Turck F; Decruyenaere J
Crit Care; 2007; 11(4):R83. PubMed ID: 17655766
[TBL] [Abstract][Full Text] [Related]
19. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring.
Jusko WJ
Ther Drug Monit; 1995 Dec; 17(6):596-601. PubMed ID: 8588227
[TBL] [Abstract][Full Text] [Related]
20. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group.
Bäckman L; Levy MF; Klintmalm G
Transplant Proc; 1995 Feb; 27(1):1124. PubMed ID: 7533361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
